Lore IO introduces COVID-19 data onboarding initiative

Lore IO Inc., providers of an AI-powered common data model, is unveiling a COVID-19 data onboarding initiative. The program is designed to help pharmaceutical organizations shorten development cycles to speed drug readiness.

The program, which is free of charge to pharma and biopharma manufacturers, allows organizations to onboard data from up to three unique sources in only 30 days instead of months which is the time it typically takes using traditional methods.

Lore IO's COVID-19 Data Onboarding Initiative will help established and emerging biopharma companies further accelerate the development and operationalization of enterprise data warehouses and commercialized analytics during pre-drug launch phases.

The program focuses on expediting the onboarding and transformation of three vendor sources of industry data, which allows the user to create a unified view of the data for analysis and accelerate the execution of their go-to-market plan.

By providing organizations with an end-to-end analytics platform, drug and device providers can easily onboard data and begin extracting value within weeks, not months, and create multiple dashboards that simplify the analysis of onboarded data to ensure just-in-time commercialization of their product launch.

"Today, simplifying and automating vendor data onboarding is essential for streamlining the time it takes to bring critical drugs to market but, to do so often requires the ability to implement AI-driven business rules to establish a common and repeatable data model approach," said Janardan Prasad, chief business officer at Lore IO. "It's never been more important to share our technology in the fight against the coronavirus, and Lore IO is committed to helping organizations who are moving fast to develop therapies and devices to combat COVID-19. Our initiative is designed to help them integrate disparate vendor data efficiently and effectively so they can shorten the time it takes to bring potentially lifesaving drugs to market."

For more information about this news, visit www.getlore.io.